Clinical Trials – Phase 2 Advisory Committee
Communique - Meeting 4, 30 March 2021
This Communique provides an update from The Australian Commission on Safety and Quality in Health Care (the Commission) on Clinical Trials – Phase 2 Advisory Committee (Advisory Committee) meetings.
We gratefully acknowledge the role of the Commission in leading this work.
Background
In November 2019, the National Clinical Trials Governance Framework (Governance Framework) was endorsed by all Health Ministers. The Governance Framework provides the first step toward the accreditation of health services for the conduct of clinical trials. The Australian Commission on Safety and Quality in Health Care (the Commission) conducted a national pilot of the Governance Framework between September 2020 and March 2021.
Clinical Trials – Phase 2 Advisory Committee: Meeting 4
The fourth meeting of the Advisory Committee was held on 30 March 2021 via videoconference. At the meeting, members received an update and early insights on the Governance Framework pilot. The Commission invited members to come forward with any feedback or issues received from their network on the pilot process.
Next Steps
In the coming weeks, the Commission project team will:
- Collate the data and information gathered through the pilot process.
- Include outcomes and recommendations in the final pilot report.
- Progress the pilot outcomes and recommendations through the Commission’s governance process and the Health Council for endorsement by all Australian Health Ministers.
The pilot report will be provided to the Advisory Committee Members at the next Advisory Committee meeting in June 2021.
The Commission will be recommending implementation from 2022 with health services being assessed against the maturity scale for the first three years.
Enquiries
If you would like to be added to the Clinical Trials – Phase 2 project distribution list and receive further correspondence about the progress of this project, please email your details to CTGovernance@safetyandquality.gov.au.